바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

572누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-5684 (MK-5684)

Castration-Resistant Prostatic Cancer; Metastasis · Castration-Resistant Prostatic Cancer

#Castration-ResistantProstaticCan#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 13상태 RECRUITING

CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Anti-CEA-CAR T (Anti-CEA-CAR T)

Lung Cancer; Colorectal Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 13상태 ACTIVE

CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3

효능 ORR 42.9%임상시험 13상태 ACTIVE

CGTAAVBiologicstaleByron LamPhase 2

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#세포유전치료#CAR-T+2

효능 ORR 82.3%임상시험 13상태 ACTIVE

ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 13상태 ACTIVE

CGTBiologicstaleShanghai First Song Biotechnolo…Phase 1

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Adult T-Cell Lymphoma/Leukaemia; Anaplastic Large Cell Lymphoma · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 13상태 ACTIVE

ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Z-endoxifen (Z-endoxifen)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 13상태 RECRUITING

ADCBiologicstaleBayerPhase 2

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 38.5%임상시험 13상태 RECRUITING

ADCBiologicstaleCelldex TherapeuticsPhase 2

CDX-011 (CDX-011)

Breast Cancer · Metastatic gpNMB Over-expressing Triple

#MetastaticgpNMBOver-expressingTr#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 21%임상시험 13상태 ACTIVE

AntibodystaleHoffmann-La RochePhase 2

Selicrelumab (Selicrelumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#항체#면역항체+2

효능 ORR 37.5%임상시험 13상태 RECRUITING

ADCBiologicstaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+1

임상시험 13상태 RECRUITING

AntibodystaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#항체#면역항체+4

효능 ORR 66.7%임상시험 13상태 ACTIVE

AntibodystaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3

효능 ORR 27.6%임상시험 13상태 ACTIVE

ADCBiologicstaleGenmabPhase 2

HuMax-TF-ADC (Tisotumab vedotin, Tisotumab vedotin (HuMax-TF-ADC))

Ovary Cancer; Cervix Cancer · Ovary Cancer

#OvaryCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 23.8%임상시험 13상태 ACTIVE

AntibodystaleRochePhase 3

rituximab (Rituxan, rituximab [MabThera/Rituxan])

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2

임상시험 13상태 ACTIVE

AntibodystaleAmgenPreclinical

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Preclinical#항체#면역항체+2

효능 ORR 10%임상시험 13상태 ACTIVE

ADCBiologicAstraZenecaalonePhase 2

AZD8205 and AZD5305 (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), saruparib)

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

임상시험 13상태 RECRUITING

ADCBiologicAbbVieadizutecanPhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 13상태 RECRUITING

CGTBiologicStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 13상태 RECRUITING

ADCBiologicAstraZenecaalonePhase 2

saruparib (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib))

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

임상시험 13상태 RECRUITING

CGTAAVBHOTFDACuratedFDABiologicSarepta TherapeuticsMicro-dystrophin cassetteApproved

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Duchenne muscular dystrophy (DMD) — ambulatory / label-expanded populations · Micro-dystrophin (AAVrh74)

#Micro-dystrophinAAVrh74#CGT#Approved#FDA승인#바이오모아추천+5

임상시험 12상태 APPROVED

ADCBiologicstaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 100%임상시험 12상태 RECRUITING

CGTBiologicstaleShenzhen Institute for Innovati…Phase 2

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 12상태 ACTIVE

ADCBiologicstaleSuzhou Suncadia Biopharmaceutic…Phase 2

SHR-A2009 (SHR-A2009)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 12상태 RECRUITING

CGTBiologicstaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 12상태 RECRUITING

35 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

MK-5684 (MK-5684)

Anti-CEA-CAR T (Anti-CEA-CAR T)

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Z-endoxifen (Z-endoxifen)

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

CDX-011 (CDX-011)

Selicrelumab (Selicrelumab)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Lirilumab (Lirilumab)

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

HuMax-TF-ADC (Tisotumab vedotin, Tisotumab vedotin (HuMax-TF-ADC))

rituximab (Rituxan, rituximab [MabThera/Rituxan])

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

AZD8205 and AZD5305 (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), saruparib)

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

saruparib (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib))

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

SHR-A2009 (SHR-A2009)

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

MK-5684 (MK-5684)

Anti-CEA-CAR T (Anti-CEA-CAR T)

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Z-endoxifen (Z-endoxifen)

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

CDX-011 (CDX-011)

Selicrelumab (Selicrelumab)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Lirilumab (Lirilumab)

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

HuMax-TF-ADC (Tisotumab vedotin, Tisotumab vedotin (HuMax-TF-ADC))

rituximab (Rituxan, rituximab [MabThera/Rituxan])

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

AZD8205 and AZD5305 (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), saruparib)

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

saruparib (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib))

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

SHR-A2009 (SHR-A2009)

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

MK-5684 (MK-5684)

Anti-CEA-CAR T (Anti-CEA-CAR T)

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Z-endoxifen (Z-endoxifen)

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

CDX-011 (CDX-011)

Selicrelumab (Selicrelumab)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Lirilumab (Lirilumab)

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

HuMax-TF-ADC (Tisotumab vedotin, Tisotumab vedotin (HuMax-TF-ADC))

rituximab (Rituxan, rituximab [MabThera/Rituxan])

Dasatinib and blinatumomab (Dasatinib and blinatumomab)